# FDA 483 - Parfums Christian Dior - June 13, 2014

Source: https://www.globalkeysolutions.net/records/483/parfums-christian-dior/d9e2e878-99fb-4970-8ad8-b6e1d4ecb6ac

> FDA 483 for Parfums Christian Dior on June 13, 2014. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Parfums Christian Dior
- Inspection Date: 2014-06-13
- Product Type: drugs
- Office Name: FDA District Office — Silver Springs, Maryland
- Summary: An FDA inspection of Parfums Christian Dior in St Jean DE Braye, France, revealed significant deficiencies in quality control and record-keeping for drug products. The firm failed to thoroughly investigate out-of-specification results and deviations, did not report serious adverse events for non-prescription drugs, and maintained inadequate batch production and control records. These issues indicate a lack of robust quality systems, posing potential risks to product quality and patient safety.

## Related Documents

- [483 - 2018-06-08](https://www.globalkeysolutions.net/records/483/parfums-christian-dior/a955bdee-9f12-4bd8-b447-1e7ef258c1d2)

## Related Officers

- [Advisor](https://www.globalkeysolutions.net/people/frederick-razzaghi/7346f6ec-1d9a-4ad3-abde-0497dcd9c8b5)

Company: https://www.globalkeysolutions.net/companies/parfums-christian-dior/59c23185-69df-4e7d-a609-bd4b8ed2af94

Office: https://www.globalkeysolutions.net/offices/fda-district-office-silver-springs-maryland/079bb75c-3759-4baa-baed-4159edd64552